![]() |
Volumn 21, Issue 1-2, 2009, Pages 41-45
|
Biosimilars: The French policy
|
Author keywords
Biosimilars; French law; Pharmacovigilance; Safety
|
Indexed keywords
BETA1A INTERFERON;
BIOLOGICAL PRODUCT;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
SMALLPOX VACCINE;
TRASTUZUMAB;
TUMOR NECROSIS FACTOR ALPHA INHIBITOR;
WART VIRUS VACCINE;
ANEMIA;
ARTICLE;
BIOTECHNOLOGICAL PROCEDURES;
BREAST CANCER;
CANCER PREVENTION;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG POTENCY;
DRUG PURITY;
DRUG RESEARCH;
DRUG SAFETY;
FRANCE;
HEALTH CARE POLICY;
HUMAN;
INFLAMMATORY DISEASE;
MEDLINE;
PATENT;
UTERINE CERVIX CANCER;
|
EID: 66249104666
PISSN: 09246479
EISSN: None
Source Type: Journal
DOI: 10.3233/JRS-2009-0458 Document Type: Article |
Times cited : (3)
|
References (7)
|